192 related articles for article (PubMed ID: 36765861)
1. Chemotherapeutics Used for High-Risk Neuroblastoma Therapy Improve the Efficacy of Anti-GD2 Antibody Dinutuximab Beta in Preclinical Spheroid Models.
Troschke-Meurer S; Zumpe M; Meißner L; Siebert N; Grabarczyk P; Forkel H; Maletzki C; Bekeschus S; Lode HN
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765861
[TBL] [Abstract][Full Text] [Related]
2. Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta.
Siebert N; Zumpe M; Schwencke CH; Biskupski S; Troschke-Meurer S; Leopold J; Zikoridse A; Lode HN
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444427
[TBL] [Abstract][Full Text] [Related]
3. Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment.
Seitz CM; Flaadt T; Mezger M; Lang AM; Michaelis S; Katz M; Syring D; Joechner A; Rabsteyn A; Siebert N; Troschke-Meurer S; Zumpe M; Lode HN; Yang SF; Atar D; Mast AS; Scheuermann S; Heubach F; Handgretinger R; Lang P; Schlegel P
Front Immunol; 2021; 12():690467. PubMed ID: 34367149
[TBL] [Abstract][Full Text] [Related]
4. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.
Ladenstein R; Pötschger U; Valteau-Couanet D; Luksch R; Castel V; Yaniv I; Laureys G; Brock P; Michon JM; Owens C; Trahair T; Chan GCF; Ruud E; Schroeder H; Beck Popovic M; Schreier G; Loibner H; Ambros P; Holmes K; Castellani MR; Gaze MN; Garaventa A; Pearson ADJ; Lode HN
Lancet Oncol; 2018 Dec; 19(12):1617-1629. PubMed ID: 30442501
[TBL] [Abstract][Full Text] [Related]
5. Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2
Chu Y; Nayyar G; Jiang S; Rosenblum JM; Soon-Shiong P; Safrit JT; Lee DA; Cairo MS
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34244307
[TBL] [Abstract][Full Text] [Related]
6. The Immunocytokine FAP-IL-2v Enhances Anti-Neuroblastoma Efficacy of the Anti-GD
Siebert N; Leopold J; Zumpe M; Troschke-Meurer S; Biskupski S; Zikoridse A; Lode HN
Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230765
[TBL] [Abstract][Full Text] [Related]
7. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice.
Zeng Y; Fest S; Kunert R; Katinger H; Pistoia V; Michon J; Lewis G; Ladenstein R; Lode HN
Mol Immunol; 2005 Jul; 42(11):1311-9. PubMed ID: 15950727
[TBL] [Abstract][Full Text] [Related]
8. A Multi-Color Flow Cytometric Assay for Quantifying Dinutuximab Binding to Neuroblastoma Cells in Tumor, Bone Marrow, and Blood.
Keyel ME; Furr KL; Kang MH; Reynolds CP
J Clin Med; 2023 Sep; 12(19):. PubMed ID: 37834874
[TBL] [Abstract][Full Text] [Related]
9. TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells.
Tran HC; Wan Z; Sheard MA; Sun J; Jackson JR; Malvar J; Xu Y; Wang L; Sposto R; Kim ES; Asgharzadeh S; Seeger RC
Clin Cancer Res; 2017 Feb; 23(3):804-813. PubMed ID: 27756784
[TBL] [Abstract][Full Text] [Related]
10. Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy.
Liu X; Wills CA; Chen L; Zhang J; Zhao Y; Zhou M; Sundstrom JM; Schell T; Spiegelman VS; Young MM; Wang HG
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35483745
[TBL] [Abstract][Full Text] [Related]
11. GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma.
Zirngibl F; Ivasko SM; Grunewald L; Klaus A; Schwiebert S; Ruf P; Lindhofer H; Astrahantseff K; Andersch L; Schulte JH; Lode HN; Eggert A; Anders K; Hundsdoerfer P; Künkele A
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34285106
[TBL] [Abstract][Full Text] [Related]
12. Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy.
Keyel ME; Reynolds CP
Biologics; 2019; 13():1-12. PubMed ID: 30613134
[TBL] [Abstract][Full Text] [Related]
13. Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy.
Nazha B; Inal C; Owonikoko TK
Front Oncol; 2020; 10():1000. PubMed ID: 32733795
[TBL] [Abstract][Full Text] [Related]
14. PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD
Siebert N; Zumpe M; Jüttner M; Troschke-Meurer S; Lode HN
Oncoimmunology; 2017; 6(10):e1343775. PubMed ID: 29123953
[TBL] [Abstract][Full Text] [Related]
15. Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity.
Shibina A; Seidel D; Somanchi SS; Lee DA; Stermann A; Maurer BJ; Lode HN; Reynolds CP; Huebener N
J Mol Med (Berl); 2013 Apr; 91(4):459-72. PubMed ID: 23052481
[TBL] [Abstract][Full Text] [Related]
16. Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy.
Lode HN; Ladenstein R; Troschke-Meurer S; Struppe L; Siebert N; Zumpe M; Ehlert K; Huber S; Glogova E; Hundsdoerfer P; Eggert A; Zaniewska-Tekieli A; Balwierz W; Wieczorek A
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444475
[TBL] [Abstract][Full Text] [Related]
17. Initiation of immunotherapy with activated natural killer cells and anti-GD2 antibody dinutuximab prior to resection of primary neuroblastoma prolongs survival in mice.
Zobel MJ; Zamora AK; Wu HW; Sun J; Lascano D; Malvar J; Wang L; Sheard MA; Seeger RC; Kim ES
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428582
[TBL] [Abstract][Full Text] [Related]
18. CD47-SIRPα Checkpoint Inhibition Enhances Neutrophil-Mediated Killing of Dinutuximab-Opsonized Neuroblastoma Cells.
Martínez-Sanz P; Hoogendijk AJ; Verkuijlen PJJH; Schornagel K; van Bruggen R; van den Berg TK; Tytgat GAM; Franke K; Kuijpers TW; Matlung HL
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503071
[TBL] [Abstract][Full Text] [Related]
19. Functional bioassays for immune monitoring of high-risk neuroblastoma patients treated with ch14.18/CHO anti-GD2 antibody.
Siebert N; Seidel D; Eger C; Jüttner M; Lode HN
PLoS One; 2014; 9(9):e107692. PubMed ID: 25226154
[TBL] [Abstract][Full Text] [Related]
20. Low CD4⁺/CD25⁺/CD127⁻ regulatory T cell- and high INF-γ levels are associated with improved survival of neuroblastoma patients treated with long-term infusion of ch14.18/CHO combined with interleukin-2.
Troschke-Meurer S; Siebert N; Marx M; Zumpe M; Ehlert K; Mutschlechner O; Loibner H; Ladenstein R; Lode HN
Oncoimmunology; 2019; 8(12):1661194. PubMed ID: 31741754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]